GENEVA, SWITZERLAND--(Marketwire - February 25, 2008) - Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd). The collaboration is focused on developing an emerging class of oral drugs, allosteric modulators, that target the metabotropic glutamate receptor 4 (mGluR4) for Parkinson’s disease and other undisclosed indications.
